Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will participate in the virtual SVB Leerink Global Healthcare Conference on February 25, 2021, with a fireside discussion scheduled for 9:20 AM ET. This event will be accessible via a live audio webcast on HOOKIPA's website, alongside an archived replay available for 30 days post-event. HOOKIPA is advancing a new class of immunotherapeutics through its proprietary arenavirus platform, focusing on treatments for cancers and infectious diseases, including a Phase 1/2 trial for HPV-positive cancers and a Phase 2 trial for a cytomegalovirus vaccine.
HOOKIPA Pharma announced the closing of its underwritten public offering, raising approximately $80.9 million through the sale of 3,910,000 shares of common stock at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each. The preferred shares are convertible into 1,000 common shares. The offering was managed by Morgan Stanley and SVB Leerink, with RBC Capital Markets as lead manager. Proceeds will likely support HOOKIPA's development of immunotherapeutics targeting infectious diseases and cancers.
HOOKIPA Pharma has announced a public offering of 3,400,000 shares of common stock priced at $11.75 each and 2,978 shares of Series A convertible preferred stock at $11,750 each, aiming to raise approximately $75 million. The offering is set to close on December 11, 2020. The underwriters have an option to purchase an additional 510,000 shares. The funds are intended for advancing its proprietary arenavirus platform targeting infectious diseases and cancers. This offering is made under a shelf registration statement with the SEC.
HOOKIPA Pharma announced an underwritten public offering of its common stock and Series A convertible preferred stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the offered shares. The offering is subject to market conditions, with no assurance regarding its completion or terms. Morgan Stanley and SVB Leerink serve as joint book-running managers. HOOKIPA is a clinical-stage biopharmaceutical company focused on immunotherapeutics targeting infectious diseases and cancers through its proprietary arenavirus platform.
HOOKIPA Pharma announced interim Phase 1 data for HB-201, a replicating monotherapy targeting HPV16-positive cancers. In a trial with 22 enrolled patients, 15 were evaluable, showing an 18% unconfirmed response rate in head and neck cancer patients who had previously received PD1 inhibitors. The treatment demonstrated a 73% disease control rate. Median progression-free survival is currently 72 days. Safety data indicated that 41% experienced treatment-related adverse events, primarily mild. HOOKIPA plans to explore further combination therapies.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported promising interim data for its CMV vaccine candidate HB-101, showing a 48% reduction in CMV viremia and no CMV disease in vaccinated kidney transplant recipients. The Phase 2 trial demonstrated a positive safety profile with a low incidence of side effects. Among the 41 participants, those receiving three doses had significantly better outcomes compared to the placebo group. The company is optimistic about progressing toward a Phase 3 trial, highlighting the vaccine's potential to address a critical unmet need in transplant care.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) reported its Q3 2020 financial results, revealing revenue of $4.0 million, up from $2.0 million in Q3 2019, primarily due to higher collaborations with Gilead. However, R&D expenses increased to $16.0 million from $11.0 million, contributing to a net loss of $13.6 million, compared to $11.4 million in the prior year. The company continues its clinical development, including the HB-201 and HB-202 oncology candidates, and is optimistic about upcoming efficacy data.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced their participation in two virtual investor conferences: the SVB Leerink Oncology 1x1 Day on November 19, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The company is focused on developing a new class of immunotherapeutics using their proprietary arenavirus platform. Their ongoing research includes a Phase 2 clinical trial for a CMV vaccine for kidney transplant patients and collaborations with Gilead Sciences for HIV and Hepatitis B treatments.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) will release its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, before the market opens. Notably, the company will not hold a conference call for this earnings release, with plans to conduct such calls only alongside its fourth-quarter earnings.
HOOKIPA develops immunotherapeutics utilizing its proprietary arenavirus platform, aiming for innovative treatments in infectious diseases and oncology.
HOOKIPA Pharma has announced the first patient dosed with HB-202, an alternate vector therapy for HPV16+ cancers in its ongoing Phase 1/2 trial. The HB-202/HB-201 regimen aims to enhance immune response, with pre-clinical studies showing a ten-fold increase. This addition could significantly impact treatment options for patients with treatment-refractory HPV16+ cancers. The trial's primary endpoint is safety and tolerability, with preliminary data expected in late 2020 or early 2021.